Altimmune’s pemvidutide showed “class-leading signals” in non-invasive assessments and has “potentially best-in-class ...

The strategic initiative will extend Metagenomi’s cash runway into the fourth quarter of 2027. That same year, the company ...

Pfizer seals the deal with Metsera for $10 billion after Novo Nordisk bowed out; President Donald Trump welcomes executives ...

With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...

In 2025, landmark obesity drug deals, China’s biotech surge, and AI’s deeper integration into pharma operations drove a year ...

Aside from offering to acquire all remaining shares of Neuphoria, existing investor Lynx1 Master Fund also announced its plan to nominate directors in the biotech’s upcoming board elections.

After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.

The appointment of Richard Pazdur, currently director of the FDA’s Oncology Center of Excellence, comes less than a week ...

Cogent Biosciences expects to file a new drug application for bezuclastinib in gastrointestinal stromal tumors early next ...

Data presented at this year’s American Heart Association Scientific Sessions in New Orleans underline rapid advancements in ...

The mid-stage failure was unexpected to analysts at BMO Capital Markets, who viewed ‘770 as mostly derisked given its similar ...

Representatives from companies such as Sanofi and Forge Biologics point to the potential for PreCheck to drive activation of ...